Doriana Fruci Selected Research

Aminopeptidases

1/2022	ERAP1 as an emerging therapeutic target for medulloblastoma.
1/2014	A role for naturally occurring alleles of endoplasmic reticulum aminopeptidases in tumor immunity and cancer pre-disposition.
1/2012	IRF1 and NF-kB restore MHC class I-restricted tumor antigen processing and presentation to cytotoxic T cells in aggressive neuroblastoma.
1/2012	Role of endoplasmic reticulum aminopeptidases in health and disease: from infection to cancer.
1/2012	ERAAP modulation: A possible novel strategy for cancer immunotherapy?
3/2011	Natural killer cells efficiently reject lymphoma silenced for the endoplasmic reticulum aminopeptidase associated with antigen processing.
2/2010	NF-kappaB, and not MYCN, regulates MHC class I and endoplasmic reticulum aminopeptidases in human neuroblastoma cells.
4/2006	Expression of endoplasmic reticulum aminopeptidases in EBV-B cell lines from healthy donors and in leukemia/lymphoma, carcinoma, and melanoma cell lines.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Doriana Fruci Research Topics

Disease

25	Neoplasms (Cancer) 01/2022 - 04/2006
13	Neuroblastoma 08/2021 - 05/2008
4	Infections 08/2020 - 10/2006
3	Rhabdomyosarcoma 01/2016 - 07/2012
2	Virus Diseases (Viral Diseases) 01/2017 - 01/2014
2	Melanoma (Melanoma, Malignant) 02/2013 - 04/2006
2	Carcinogenesis 12/2012 - 05/2008
2	Lymphoma (Lymphomas) 03/2011 - 04/2006
1	COVID-19 02/2021
1	Behcet Syndrome (Behcet's Syndrome) 01/2019
1	Rheumatoid Arthritis 01/2019
1	Retinoblastoma (Glioblastoma, Retinal) 01/2016
1	Hepatoblastoma 01/2016
1	Wilms Tumor (Wilm's Tumor) 01/2016
1	Non-alcoholic Fatty Liver Disease 10/2012
1	Hepatocellular Carcinoma (Hepatoma) 10/2012
1	Fibrosis (Cirrhosis) 10/2012
1	Sarcoma (Soft Tissue Sarcoma) 07/2012
1	Residual Neoplasm 07/2012
1	T-Cell Lymphoma (Lymphoma, T Cell) 03/2011
1	Leukocytosis (Pleocytosis) 06/2009
1	Thrombotic Microangiopathies 06/2009
1	Inflammation (Inflammations) 10/2006
1	Leukemia 04/2006
1	Carcinoma (Carcinomatosis) 04/2006
1	Myotonic Dystrophy (Dystrophia Myotonica) 03/2006
1	Renal Insufficiency (Renal Failure) 08/2005
1	Hypertension (High Blood Pressure) 08/2005
1	Essential Hypertension 08/2005

Drug/Important Bio-Agent (IBA)

8	AminopeptidasesIBA 01/2022 - 04/2006
5	Peptides (Polypeptides)IBA 01/2022 - 04/2006
5	MicroRNAs (MicroRNA)IBA 08/2020 - 05/2008
4	EnzymesIBA 02/2021 - 10/2006
4	LigandsIBA 01/2021 - 02/2013
3	Histocompatibility Antigens Class IIBA 01/2022 - 03/2011
3	NF-kappa B (NF-kB)IBA 08/2021 - 02/2010
3	3' Untranslated Regions (3' UTR)IBA 08/2020 - 03/2006
3	Proteins (Proteins, Gene)FDA Link 01/2019 - 07/2012
2	Messenger RNA (mRNA)IBA 08/2020 - 05/2008
2	EpitopesIBA 01/2019 - 03/2009
2	Pharmaceutical PreparationsIBA 01/2016 - 08/2005
2	Neoplasm Antigens (Tumor Antigens)IBA 01/2014 - 01/2012
2	Peptide Hydrolases (Proteases)FDA Link 10/2006 - 04/2006
1	Multifunctional EnzymesIBA 01/2022
1	Immune Checkpoint InhibitorsIBA 01/2022
1	nutlin 3IBA 01/2021
1	HLA-B Antigens (HLA-B)IBA 01/2019
1	AutoantigensIBA 01/2019
1	VimentinIBA 01/2019
1	Myosin Heavy Chains (Myosin Heavy Chain)IBA 01/2019
1	Biomarkers (Surrogate Marker)IBA 08/2017
1	Immune Checkpoint ProteinsIBA 08/2017
1	Viral ProteinsIBA 01/2017
1	Antiviral Agents (Antivirals)IBA 01/2017
1	micaIBA 01/2017
1	ATP-Binding Cassette Transporters (ABC Transporters)IBA 01/2016
1	Adenosine Triphosphate (ATP)IBA 01/2016
1	Indicators and Reagents (Reagents)IBA 09/2015
1	Indoleamine-Pyrrole 2,3,-Dioxygenase (Indoleamine 2,3 Dioxygenase)IBA 02/2013
1	Immunosuppressive Agents (Immunosuppressants)IBA 02/2013
1	Dinoprostone (PGE2)FDA Link 02/2013
1	Antineoplastic Agents (Antineoplastics)IBA 02/2013
1	Sodium-Potassium-Exchanging ATPase (Sodium, Potassium ATPase)IBA 01/2013
1	Hyaluronic Acid (Hyaluronan)IBA 10/2012
1	Biological ProductsIBA 07/2012
1	multidrug resistance-associated protein 1IBA 07/2012
1	Multidrug Resistance-Associated ProteinsIBA 07/2012
1	Glycoproteins (Glycoprotein)IBA 07/2012
1	Platelet Membrane GlycoproteinsIBA 06/2009
1	Shiga Toxins (Vero Toxin)IBA 06/2009
1	HLA-A2 Antigen (HLA A2 Antigen)IBA 03/2009
1	AntagomirsIBA 05/2008
1	Peptidyl-Dipeptidase A (Angiotensin Converting Enzyme)IBA 08/2005
1	Cyclosporine (Ciclosporin)FDA LinkGeneric 08/2005
1	Plasminogen Activator Inhibitor 1IBA 08/2005

Therapy/Procedure

7	Immunotherapy 01/2022 - 03/2009
5	Therapeutics 01/2022 - 05/2008
3	Drug Therapy (Chemotherapy) 01/2016 - 07/2012
1	Induction Chemotherapy 09/2019